Atreca Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 12, 2020 16:30 ET
|
Atreca, Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces Participation in Two Upcoming Virtual Investor Conferences
April 06, 2020 16:30 ET
|
Atreca, Inc.
SOUTH SAN FRANCISCO, Calif., April 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Reports Fourth Quarter and Full Year 2019 Financial Results
March 11, 2020 16:30 ET
|
Atreca, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated...
Atreca to Present at the Cowen and Company 40th Annual Health Care Conference
February 24, 2020 16:30 ET
|
Atreca, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors
February 13, 2020 16:30 ET
|
Atreca, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces Strategic Research Collaboration with Merck to Identify Novel Antibody Targets in Oncology
February 05, 2020 16:05 ET
|
Atreca, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through...
Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101
December 03, 2019 08:00 ET
|
Atreca, Inc.
First IND clearance of a clinical candidate derived from Atreca’s differentiated drug discovery platform Phase 1b clinical trial in patients with solid tumors to begin in early 2020 ...
Atreca to Present at Two Upcoming Investor Conferences
November 14, 2019 08:00 ET
|
Atreca, Inc.
REDWOOD CITY, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the...
Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments
November 12, 2019 16:05 ET
|
Atreca, Inc.
REDWOOD CITY, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the...
Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 05, 2019 08:00 ET
|
Atreca, Inc.
REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the...